Jennifer Humes - 20 Apr 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: Chief Accounting Officer
Issuer ticker: ROIV
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 18:26:12 UTC
Prior SEC filing: 10 Apr 2026
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jo Chen, as Attorney-in-Fact for Jennifer Humes

Key filing fact

Jennifer Humes filed Form 4 for Roivant Sciences Ltd. (ROIV) on 22 Apr 2026.

Key facts

This page summarizes Jennifer Humes's Form 4 filing for Roivant Sciences Ltd. (ROIV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Apr 2026, 18:26.

Change

Previous filing in this sequence was filed on 10 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002058012 Primary reporting owner

Humes Jennifer

Relationship: Chief Accounting Officer
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: /s/ Jo Chen, as Attorney-in-Fact for Jennifer Humes
Signature date: 22 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Award

Transaction value
Shares: +29,173
Change %: +35%
Price: $0.000000^*
Shares after: 113,364
Date: 20 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +27,157
Change %
Price: $0.000000^*
Shares after: 27,157
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 27,157
Exercise price: $29.08
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects an award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2026. These RSUs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in twelve (12) successive equal quarterly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through each applicable vesting date.

Footnote F2

Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through each applicable vesting date.